Citadel Advisors’s AIM ImmunoTech AIM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-487
| Closed | -$5.95K | – | 15816 |
|
|
2025
Q1 | $5.95K | Sell |
487
-3,106
| -86% | -$49.9K | ﹤0.01% | 13783 |
|
|
2024
Q4 | $71.1K | Sell |
3,593
-989
| -22% | -$23K | ﹤0.01% | 11943 |
|
|
2024
Q3 | $124K | Buy |
4,582
+3,601
| +367% | +$120K | ﹤0.01% | 10832 |
|
|
2024
Q2 | $36.5K | Buy |
+981
| New | +$41.6K | ﹤0.01% | 12076 |
|
|
2024
Q1 | – | Sell |
-341
| Closed | -$15K | – | 15912 |
|
|
2023
Q4 | $15K | Buy |
+341
| New | +$15.9K | ﹤0.01% | 12855 |
|
|
2023
Q2 | – | Sell |
-300
| Closed | -$12.9K | – | 15826 |
|
|
2023
Q1 | $12.9K | Sell |
300
-403
| -57% | -$20.9K | ﹤0.01% | 13384 |
|
|
2022
Q4 | $21.9K | Buy |
+703
| New | +$32.7K | ﹤0.01% | 13071 |
|
|
2022
Q1 | – | Sell |
-411
| Closed | -$37K | – | 15382 |
|
|
2021
Q4 | $37K | Buy |
+411
| New | +$63.6K | ﹤0.01% | 13405 |
|
|
2021
Q2 | – | Sell |
-1,034
| Closed | -$234K | – | 15072 |
|
|
2021
Q1 | $234K | Buy |
+1,034
| New | +$233K | ﹤0.01% | 11407 |
|
|
2020
Q4 | – | Sell |
-166
| Closed | -$36K | – | 11975 |
|
|
2020
Q3 | $36K | Buy |
+166
| New | +$41.5K | ﹤0.01% | 9717 |
|
|
2019
Q1 | – | Sell |
-32
| Closed | -$26K | – | 10449 |
|
|
2018
Q4 | $26K | Buy |
32
+8
| +33% | +$7.34K | ﹤0.01% | 8671 |
|
|
2018
Q3 | $24K | Buy |
24
+11
| +85% | +$13.4K | ﹤0.01% | 8987 |
|
|
2018
Q2 | $18K | Sell |
13
-33
| -72% | -$48.3K | ﹤0.01% | 8674 |
|
|
2018
Q1 | $79K | Buy |
46
+35
| +318% | +$73.1K | ﹤0.01% | 7795 |
|
|
2017
Q4 | $16K | Buy |
+11
| New | +$15.8K | ﹤0.01% | 7870 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$5K | – | 8429 |
|
|
2016
Q2 | $5K | Sell |
1
-3
| -75% | -$19.7K | ﹤0.01% | 6751 |
|
|
2016
Q1 | $31K | Sell |
4
-2
| -33% | -$12.8K | ﹤0.01% | 6378 |
|
|
2015
Q4 | $26K | Buy |
+6
| New | +$40.8K | ﹤0.01% | 7778 |
|
|
2014
Q4 | – | Sell |
-1
| Closed | -$21K | – | 9163 |
|
|
2014
Q3 | $21K | Hold |
1
| – | – | ﹤0.01% | 7407 |
|
|
2014
Q2 | $9K | Sell |
1
-4
| -80% | -$71.6K | ﹤0.01% | 7622 |
|
|
2014
Q1 | $108K | Buy |
+5
| New | +$106K | ﹤0.01% | 6130 |
|
|
2013
Q4 | – | Sell |
-2
| Closed | -$25K | – | 7545 |
|
|
2013
Q3 | $25K | Buy |
+2
| New | +$25.2K | ﹤0.01% | 6126 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 6381 |
|
Other funds holding AIM
CB
HI
HI
DB
Citadel Advisors's AIM Position: Q2 2025 in Review
Citadel Advisors sold out of AIM ImmunoTech (AIM) in Q2 2025, closing a stake of 487 shares — an estimated $5.95K sold.
Citadel Advisors first reported a position in AIM in Q3 2013 and held it in 22 quarters. The position peaked at $234K in Q1 2021. 12 funds tracked by Wall St. Rank hold AIM as of Q2 2025.
- Citadel Advisors reported no remaining AIM ImmunoTech position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 487 AIM ImmunoTech shares in Q2 2025, an estimated $5.95K.
- Citadel Advisors first reported a position in AIM ImmunoTech in Q3 2013 and held it in 22 quarters.
- Citadel Advisors's AIM ImmunoTech position peaked at $234K in Q1 2021.
- 12 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.